Cargando…
MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study
OBJECTIVE: RESTORE was a randomized, partially placebo-controlled exploratory study evaluating multiple sclerosis (MS) disease activity during a 24-week interruption of natalizumab. METHODS: Eligible patients were relapse-free through the prior year on natalizumab and had no gadolinium-enhancing les...
Autores principales: | Fox, Robert J., Cree, Bruce A.C., De Sèze, Jerome, Gold, Ralf, Hartung, Hans-Peter, Jeffery, Douglas, Kappos, Ludwig, Kaufman, Michael, Montalbán, Xavier, Weinstock-Guttman, Bianca, Anderson, Britt, Natarajan, Amy, Ticho, Barry, Duda, Petra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4011468/ https://www.ncbi.nlm.nih.gov/pubmed/24682966 http://dx.doi.org/10.1212/WNL.0000000000000355 |
Ejemplares similares
-
Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients
por: Plavina, Tatiana, et al.
Publicado: (2017) -
Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS
por: Kappos, Ludwig, et al.
Publicado: (2015) -
Natalizumab-PML survivors with subsequent MS treatment: Clinico-radiologic outcome
por: Maillart, Elisabeth, et al.
Publicado: (2017) -
Aquaporin-4 antibodies in patients treated with natalizumab for suspected MS
por: Gahlen, Anna, et al.
Publicado: (2017) -
Pharmacodynamics of natalizumab extended interval dosing in MS
por: Zhovtis Ryerson, Lana, et al.
Publicado: (2020)